| Company/Division name | Civica Rx |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 250 |
| Year reshoring announced: | 2022 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 124.5 |
| City reshored to: | Petersburg |
| State(s) reshored to: | VA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | insulin |
| What non-domestic negative factors made offshoring less attractive? | Supply chain interruption risk/Natural disaster risk/Political instability |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Proximity to customers/market, Biden, bill to cap insulin prices |
